Centogene presented the figures for the first nine months of the current year on Wednesday. In the US pre-exchange, the company’s share price is currently rising by almost 8 percent. The Rostock-based biotech company increased its sales from EUR 33.5 million to EUR 58.1 million. The third quarter alone contributed 36.3 million euros after 11.6 million euros in the same period of the previous year. The reason for the explosive sales growth is the significantly expanded COVID-19 test activities of Centogene. It operates test centers for COVID-19 infections at various airports such as the one in Frankfurt in cooperation with Lufthansa.
Especially in August and September, the test numbers rose significantly, as if from one Presentation of Centogene on the nine month figures emerges. “In the third quarter, we were able to significantly increase our sales compared to the previous year, which can be attributed to the fact that we were able to use our core competence in the field of precise medical diagnostics to quickly turn around and offer solutions to combat the COVID-19 pandemic”, said Richard Stoffelen, Chief Financial Officer at Centogene, about the Quarterly and nine-month figures.